Navigation Links
WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
Date:7/20/2009

SHANGHAI, July 20 /PRNewswire-Asia/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading pharmaceutical, biotechnology and medical device R&D outsourcing company with operations in China and the United States, today announced that it will release financial results for the second quarter of 2009 after the New York Stock Exchange closes on Tuesday, August 11, 2009 (which will be Wednesday morning, August 12, 2009 Shanghai time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO )

The earnings release will be available on the investor relations section of its website at http://www.wuxiapptec.com .

Following the earnings announcement, WuXi PharmaTech senior management will host a conference call at 8:00 am (U.S. Eastern) / 5:00 am (U.S. Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Wednesday, August 12, 2009, to discuss the second-quarter 2009 financial results and recent business activities. The conference call may be accessed by calling:

        United States: 1-866-519-4004
        China (Landline): 800-819-0121
        China (Mobile): 400-620-8038
        Hong Kong: 800-933-053
        United Kingdom: 0-808-234-6646
        International: +65-6735-7955
        Conference ID: 19244798
        Web PIN: 8656

    A telephone replay will be available two hours after the call's completion
at:

        United States: 1-866-214-5335
        China North: 10-800-714-0386
        China South: 10-800-140-0386
        Hong Kong: 800-901-596
        United Kingdom: 0-800-731-7846
        International: +61-2-8235-5000
        Conference ID # 19244798

A live webcast of the conference call and replay will be available in the investor relations section of WuXi PharmaTech's website at http://www.wuxiapptec.com .

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies with a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to help its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .

    For more information, please contact:

     Ronald Aldridge
     Director of Investor Relations
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +1-201-585-2048
     Email: Ron_Aldridge@wuxiapptec.com

     Web:http://www.wuxiapptec.com

'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. WuXi PharmaTech Receives Award from BASF
2. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
3. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
4. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
5. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
6. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
7. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
8. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
9. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
10. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
11. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... ... January 12, 2017 , ... Each year, Crain’s Detroit Business News ranks the ... evaluates the patent estate of a company, its impact and significance, and the likelihood ... the way in technologies that transform energy sources such as low dose X-ray and ...
(Date:1/12/2017)... ... January 12, 2017 , ... After ... Lisa Rosendahl’s doctors gave her only a few months to live. Now a ... that has stabilized Rosendahl’s disease and increased both the quantity and quality of ...
(Date:1/12/2017)... and Pune, India , January 12, 2017 ... Toxicity Testing Market by Type and End Users - Global Opportunity Analysis and Industry ... million by 2022 from $2,921 million in 2015, growing at a CAGR of 15.07% ... ... Allied Market Research Logo ...
(Date:1/11/2017)... Colo. (PRWEB) , ... January 11, 2017 , ... ... the journal Clinical Cancer Research show early promise of the investigational anti-cancer agent ... despite a median 5 previous treatment regimens. Twenty-seven percent of these heavily pretreated ...
Breaking Biology Technology:
(Date:1/6/2017)... -- Delta ID Inc., a leader in consumer-grade iris scanning ... CES® 2017. Delta ID has collaborated with Gentex Corporation ... of iris scanning as a secure, reliable and convenient ... car, and as a way to elevate the security ... ID and Gentex will demonstrate (booth #7326 LVCC) a ...
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
Breaking Biology News(10 mins):